嵌合抗原受体T细胞治疗儿童急性B淋巴细胞白血病的研究进展

Research progress of chimeric antigen receptor T cells in the treatment of childhood acute B lymphoblastic leukemia

急性淋巴细胞白血病(acute lymphocytic leukemia, ALL)是儿童最常见的血液系统恶性肿瘤。虽然到目前为止存活率超过85%,但化疗及造血干细胞移植(hematopoietic stem cell transplantation, HSCT)等治疗手段对于难治/复发性ALL患儿的治疗效果较差,首次复发后的5年生存率仅为30%~50%,而再次复发后的5年生存率低于20%,因此成为儿童ALL死亡的主要原因之一[1]。

Acute lymphoblastic leukemia(ALL) is the most common malignant tumor in childhood. With the continuous improvement of chemotherapy and the development of hematopoietic stem cell transplantation, the 5-year survival rate of children can reach about 90%. However, about 10% of the children with ALL are refractory or relapse, and the survival rate and cure rate of these children are very low. Chimeric antigen receptor(CAR)-T cell therapy can greatly improve the survival and cure rate of refractory/recurrent B-ALL. Therefore, this article will briefly review the current situation of CAR-T in the treatment of refractory/recurrent B-ALL in children.